SG155183A1 - Process for the preparation of glycosylated interferon beta - Google Patents
Process for the preparation of glycosylated interferon betaInfo
- Publication number
- SG155183A1 SG155183A1 SG200905181-4A SG2009051814A SG155183A1 SG 155183 A1 SG155183 A1 SG 155183A1 SG 2009051814 A SG2009051814 A SG 2009051814A SG 155183 A1 SG155183 A1 SG 155183A1
- Authority
- SG
- Singapore
- Prior art keywords
- interferon beta
- preparation
- glycosylated interferon
- glycosylated
- purification
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0031—Serum-free culture media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/92—Medium free of human- or animal-derived components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/99—Serum-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2005/054220 WO2007022799A1 (en) | 2005-08-26 | 2005-08-26 | Process for the preparation of glycosylated interferon beta |
Publications (1)
Publication Number | Publication Date |
---|---|
SG155183A1 true SG155183A1 (en) | 2009-09-30 |
Family
ID=35788670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200905181-4A SG155183A1 (en) | 2005-08-26 | 2005-08-26 | Process for the preparation of glycosylated interferon beta |
Country Status (22)
Country | Link |
---|---|
US (2) | US20080219952A1 (zh) |
EP (2) | EP2390263A1 (zh) |
JP (1) | JP4944112B2 (zh) |
KR (1) | KR101276367B1 (zh) |
CN (1) | CN101282990B (zh) |
AU (1) | AU2005335900B2 (zh) |
BR (1) | BRPI0520498B8 (zh) |
DK (1) | DK1917276T3 (zh) |
EA (1) | EA015901B1 (zh) |
ES (1) | ES2664924T3 (zh) |
HK (1) | HK1120052A1 (zh) |
HR (1) | HRP20180579T1 (zh) |
HU (1) | HUE038947T2 (zh) |
IL (1) | IL189738A (zh) |
LT (1) | LT1917276T (zh) |
MX (1) | MX2008002596A (zh) |
PL (1) | PL1917276T3 (zh) |
PT (1) | PT1917276T (zh) |
RS (1) | RS57549B1 (zh) |
SG (1) | SG155183A1 (zh) |
SI (1) | SI1917276T1 (zh) |
WO (1) | WO2007022799A1 (zh) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT1917276T (lt) | 2005-08-26 | 2018-05-25 | Ares Trading S.A. | Glikozilinto interferono beta gavimo būdas |
WO2007065918A2 (en) * | 2005-12-09 | 2007-06-14 | Ares Trading S.A. | Method for purifying fsh or a fsh mutant |
NZ575328A (en) | 2006-09-13 | 2012-06-29 | Abbott Lab | Cell culture improvements |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
NZ580686A (en) | 2007-05-02 | 2012-11-30 | Ambrx Inc | Modified interferon beta polypeptides and their uses |
AU2008314689A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an Fc-containing protein |
US20100249381A1 (en) * | 2007-10-22 | 2010-09-30 | David Delvaille | Method for Purifying FC-Fusion Proteins |
DE102008051574A1 (de) * | 2008-10-14 | 2010-04-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Herstellung von Interferon-beta und deren Varianten |
AU2009307737B2 (en) | 2008-10-20 | 2015-07-23 | Abbvie Inc. | Viral inactivation during purification of antibodies |
JP5808249B2 (ja) | 2008-10-20 | 2015-11-10 | アッヴィ・インコーポレイテッド | プロテインaアフィニティークロマトグラフィーを用いる抗体の単離および精製 |
WO2010089126A2 (en) * | 2009-02-09 | 2010-08-12 | Roche Glycart Ag | Immunoglobulin glycosylation pattern analysis |
DE102009032179A1 (de) * | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
US20120177603A1 (en) * | 2009-07-07 | 2012-07-12 | Biogenerix Ag | Method for the purification of interferon-b |
US20110136682A1 (en) * | 2009-12-04 | 2011-06-09 | Momenta Pharmaceuticals, Inc. | Antennary fucosylation in glycoproteins from cho cells |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
KR101979045B1 (ko) * | 2011-10-01 | 2019-05-15 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물 |
CN102533658B (zh) * | 2011-12-08 | 2014-06-04 | 深圳新鹏生物工程有限公司 | 制备人干扰素β1a的细胞的培养方法和培养基及其应用 |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
CN102757937B (zh) * | 2012-07-05 | 2014-04-16 | 复旦大学附属中山医院 | 一种培养神经元的含酚红无血清培养体系以及酚红新用途 |
CA2883272A1 (en) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9310344B2 (en) | 2013-06-14 | 2016-04-12 | Dionex Corporation | HILIC/anion-exchange/cation-exchange multimodal media |
US9169331B2 (en) | 2012-12-21 | 2015-10-27 | Dionex Corporation | Separation of glycans by mixed-mode liquid chromatography |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
LT6164B (lt) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
CN106132983B (zh) | 2014-04-04 | 2021-03-26 | 阿雷斯贸易股份有限公司 | 新型IFN-β蛋白类似物 |
EA027609B9 (ru) * | 2015-04-29 | 2017-11-30 | Тютор С.А.С.И.Ф.И.А. | Способ получения интерферона бета-1альфа и фармацевтическая композиция, содержащая интерферон бета-1альфа |
WO2016196621A1 (en) * | 2015-06-01 | 2016-12-08 | Biogen Ma Inc. | Manganese supplementation for control of glycosylation in mammalian cell culture process |
KR20210009982A (ko) * | 2019-07-18 | 2021-01-27 | 에이비온 주식회사 | 2당화된 인터페론-베타 단백질의 정제 방법 |
CN111563198B (zh) * | 2020-04-16 | 2023-07-25 | 百度在线网络技术(北京)有限公司 | 一种物料召回方法、装置、设备及存储介质 |
CN117024561B (zh) * | 2023-10-10 | 2024-02-20 | 哈药集团生物工程有限公司 | 一种聚乙二醇修饰干扰素的纯化方法 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326859A (en) | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
ZA803943B (en) | 1979-07-31 | 1981-06-24 | Hoffmann La Roche | Homogeneous fibroblast interferon and method for manufacture thereof |
EP0070906B1 (en) | 1981-02-04 | 1986-10-15 | Juridical Foundation Japanese Foundation For Cancer Research | Human interferon-beta gene |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5266476A (en) | 1985-06-18 | 1993-11-30 | Yeda Research & Development Co., Ltd. | Fibrous matrix for in vitro cell cultivation |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US4879111A (en) | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
US5045468A (en) | 1986-12-12 | 1991-09-03 | Cell Enterprises, Inc. | Protein-free culture medium which promotes hybridoma growth |
NO162160C (no) | 1987-01-09 | 1989-11-15 | Medi Cult As | Serumfritt vekstmedium, samt anvendelse derav. |
DE3712564A1 (de) | 1987-04-14 | 1988-11-24 | Bioferon Biochem Substanz | Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta |
IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
ATE148171T1 (de) * | 1989-02-21 | 1997-02-15 | Univ Washington | Modifizierte formen von fortpflanzungshormonen |
US5338835A (en) * | 1989-02-21 | 1994-08-16 | Washington University | CTP-extended form of FSH |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5665868A (en) | 1990-09-14 | 1997-09-09 | Vittal Mallya Scientific Research Foundation | Chromatographic agent and its use for the separation or proteins, polypeptides of metals |
KR100234520B1 (ko) | 1991-01-18 | 1999-12-15 | 그레고리 아보트 | 종양괴사인자 매개병 치료용 의약품 조성물 |
US5508261A (en) * | 1991-06-18 | 1996-04-16 | University Of Medicine & Dentistry Of New Jersey | Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same |
DE4128319A1 (de) | 1991-08-27 | 1993-03-04 | Bioferon Biochem Substanz | Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen |
SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
DK1396542T3 (da) | 1992-10-23 | 2011-06-06 | Genetics Inst Llc | P-selectin ligand protein |
EP0666312A1 (en) | 1994-02-08 | 1995-08-09 | Wolfgang A. Renner | Process for the improvement of mammalian cell growth |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
AU720337B2 (en) | 1995-02-17 | 2000-05-25 | Stichting Dienst Landbouwkundig Onderzoek | Production of biologically active recombinant bovine follicle stimulating hormone (REC bFSH) in the baculovirus expression system |
AUPN801296A0 (en) | 1996-02-12 | 1996-03-07 | Csl Limited | Stabilised growth hormone formulation and method of preparation thereof |
DE69623109T2 (de) | 1996-04-19 | 2002-12-12 | Nestle Sa | Menschliche immortalisierte Colon-Epithelialzellen |
JP2000517188A (ja) * | 1996-08-30 | 2000-12-26 | ライフ テクノロジーズ,インコーポレイテッド | 無血清哺乳動物細胞培養培地およびその使用 |
IT1287138B1 (it) | 1996-11-07 | 1998-08-04 | Ibsa Inst Biochimique Sa | Procedimento per la separazione e purificazione di fsh e lh |
US6162905A (en) * | 1996-11-07 | 2000-12-19 | Ibsa Institut Biochimique S.A. | FSH and LH separation and purification process |
PL191400B1 (pl) | 1996-11-15 | 2006-05-31 | Genentech Inc | Sposób izolowania neurotrofiny z mieszaniny białek i kompozycja neurotrofiny |
US5883073A (en) * | 1997-04-03 | 1999-03-16 | Washington University | Single-chain double-alpha peptide |
US6013253A (en) | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
KR100826621B1 (ko) * | 1997-09-23 | 2008-05-02 | 렌트슐러 비오테히놀로기 게엠베하 | 액상 인터페론-베타 제제 |
US5990288A (en) * | 1997-10-21 | 1999-11-23 | Vitro Diagnostics, Inc. | Method for purifying FSH |
US6414123B1 (en) | 1997-10-21 | 2002-07-02 | Vitro Diagnostics, Inc. | Method for purifying FSH |
PT1075281E (pt) | 1998-04-28 | 2004-11-30 | Applied Research Systems | Conjugados poliol-ifn-beta |
US20030153042A1 (en) | 1998-07-28 | 2003-08-14 | California Institute Of Technology | Expression of functional eukaryotic proteins |
US20040010134A1 (en) * | 2000-04-12 | 2004-01-15 | Rosen Craig A. | Albumin fusion proteins |
DK1169349T3 (da) | 1999-04-16 | 2007-07-30 | Inst Massone S A | Proces til fremstilling af gonadotropinsammensætninger |
US7431921B2 (en) * | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
WO2001058493A1 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | Conjugates of follicle stimulating hormones |
KR100808149B1 (ko) * | 2000-02-22 | 2008-02-29 | 라보라토리스 세로노 에스.에이. | 정제된 lh |
US20030017550A1 (en) * | 2001-01-22 | 2003-01-23 | Pang Danny Zhong Der | DNA sequences encoding fusion proteins comprising IFN-beta and TM-alpha1 |
CA2469846A1 (en) * | 2001-02-27 | 2002-09-26 | Maxygen Aps | New interferon beta-like molecules |
US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
AU784808B2 (en) | 2001-04-02 | 2006-06-29 | Kedrion Melville Inc. | Prion and viral clearance process |
RU2004102500A (ru) * | 2001-06-29 | 2005-04-10 | Максиген Апс (Dk) | Композиции интерферонов |
US7226903B2 (en) * | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
WO2004050679A2 (en) | 2001-10-22 | 2004-06-17 | Applied Research Systems Ars Holding N.V. | Mutant glycoproteins |
DK1463751T3 (da) * | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albuminfusionsproteiner. |
US20060083715A1 (en) * | 2002-03-12 | 2006-04-20 | Steven Glazer | Interferon beta-like molecules for treatment of stroke |
GEP20084499B (en) | 2002-07-17 | 2008-10-10 | Biogen Idec Inc | USE OF INTERFERON-ß FOR TREATMENT OF RENAL FAILURE |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
UA88879C2 (en) | 2003-09-02 | 2009-12-10 | Эплайд Рисерч Системз Эрс Холдинг Н.В. | Fsh glycosylation mutant |
KR100524872B1 (ko) * | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
KR100524871B1 (ko) * | 2003-12-04 | 2005-10-31 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
EA008924B1 (ru) | 2003-12-22 | 2007-08-31 | Арес Трейдинг С.А. | Способ очистки фсг |
US7598356B2 (en) | 2004-07-08 | 2009-10-06 | Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center | Method for purifying a protein of the cystine-knot superfamily |
TWI384069B (zh) * | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
EP1809663B1 (en) * | 2004-11-09 | 2008-09-17 | Ares Trading S.A. | Method for purifying fsh |
LT1917276T (lt) | 2005-08-26 | 2018-05-25 | Ares Trading S.A. | Glikozilinto interferono beta gavimo būdas |
WO2007065918A2 (en) * | 2005-12-09 | 2007-06-14 | Ares Trading S.A. | Method for purifying fsh or a fsh mutant |
CN101370825B (zh) * | 2006-01-17 | 2012-10-10 | 默克雪兰诺有限公司 | 新颖的fsh糖基化突变体d3n |
AU2008314689A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an Fc-containing protein |
US20100249381A1 (en) * | 2007-10-22 | 2010-09-30 | David Delvaille | Method for Purifying FC-Fusion Proteins |
-
2005
- 2005-08-26 LT LTEP05784517.4T patent/LT1917276T/lt unknown
- 2005-08-26 SG SG200905181-4A patent/SG155183A1/en unknown
- 2005-08-26 PT PT57845174T patent/PT1917276T/pt unknown
- 2005-08-26 KR KR20087006783A patent/KR101276367B1/ko active IP Right Grant
- 2005-08-26 BR BRPI0520498A patent/BRPI0520498B8/pt active IP Right Grant
- 2005-08-26 CN CN2005800517905A patent/CN101282990B/zh active Active
- 2005-08-26 JP JP2008527315A patent/JP4944112B2/ja active Active
- 2005-08-26 US US12/064,422 patent/US20080219952A1/en not_active Abandoned
- 2005-08-26 AU AU2005335900A patent/AU2005335900B2/en active Active
- 2005-08-26 MX MX2008002596A patent/MX2008002596A/es active IP Right Grant
- 2005-08-26 EP EP20110161155 patent/EP2390263A1/en not_active Withdrawn
- 2005-08-26 PL PL05784517T patent/PL1917276T3/pl unknown
- 2005-08-26 EP EP05784517.4A patent/EP1917276B1/en active Active
- 2005-08-26 WO PCT/EP2005/054220 patent/WO2007022799A1/en active Application Filing
- 2005-08-26 DK DK05784517.4T patent/DK1917276T3/en active
- 2005-08-26 EA EA200800669A patent/EA015901B1/ru not_active IP Right Cessation
- 2005-08-26 RS RS20180470A patent/RS57549B1/sr unknown
- 2005-08-26 ES ES05784517.4T patent/ES2664924T3/es active Active
- 2005-08-26 SI SI200532202T patent/SI1917276T1/en unknown
- 2005-08-26 HU HUE05784517A patent/HUE038947T2/hu unknown
-
2008
- 2008-02-25 IL IL189738A patent/IL189738A/en active IP Right Grant
- 2008-12-23 HK HK08113888A patent/HK1120052A1/xx unknown
-
2011
- 2011-06-14 US US13/159,864 patent/US8993724B2/en active Active
-
2018
- 2018-04-11 HR HRP20180579TT patent/HRP20180579T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005335900B2 (en) | 2012-03-29 |
AU2005335900A1 (en) | 2007-03-01 |
US20110305669A1 (en) | 2011-12-15 |
LT1917276T (lt) | 2018-05-25 |
EP2390263A1 (en) | 2011-11-30 |
RS57549B1 (sr) | 2018-10-31 |
IL189738A0 (en) | 2008-08-07 |
PT1917276T (pt) | 2018-06-11 |
US20080219952A1 (en) | 2008-09-11 |
WO2007022799A1 (en) | 2007-03-01 |
ES2664924T3 (es) | 2018-04-24 |
HK1120052A1 (en) | 2009-03-20 |
DK1917276T3 (en) | 2018-05-07 |
BRPI0520498A2 (pt) | 2010-07-13 |
BRPI0520498B1 (pt) | 2018-11-06 |
JP4944112B2 (ja) | 2012-05-30 |
PL1917276T3 (pl) | 2018-08-31 |
CN101282990B (zh) | 2013-04-03 |
EP1917276A1 (en) | 2008-05-07 |
KR101276367B1 (ko) | 2013-06-25 |
SI1917276T1 (en) | 2018-05-31 |
BRPI0520498B8 (pt) | 2021-05-25 |
EP1917276B1 (en) | 2018-03-21 |
JP2009505645A (ja) | 2009-02-12 |
HUE038947T2 (hu) | 2018-12-28 |
MX2008002596A (es) | 2008-03-14 |
HRP20180579T1 (hr) | 2018-05-18 |
EA015901B1 (ru) | 2011-12-30 |
KR20080048490A (ko) | 2008-06-02 |
US8993724B2 (en) | 2015-03-31 |
CN101282990A (zh) | 2008-10-08 |
EA200800669A1 (ru) | 2008-12-30 |
IL189738A (en) | 2012-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG155183A1 (en) | Process for the preparation of glycosylated interferon beta | |
PL1885753T3 (pl) | Wytwarzanie rekombinowanego białka wiążącego IL-18 | |
IL178541A0 (en) | O-linked glycoforms of polypeptides and method to manufacture them | |
ZA200702523B (en) | Process for the purification of 1,4-butanediol | |
EP1897951A3 (en) | Composition and methods for producing steviol and steviol glycosides | |
ZA200705874B (en) | Process for producing polypeptide mixtures using hydrogenolysis | |
TW200508201A (en) | Novel process for the preparation of roflumilast | |
MY147732A (en) | Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines | |
EP1873131A4 (en) | METHOD FOR PRODUCING A CERAMIC SUBSTRATE AND CERAMIC SUBSTRATE | |
MXPA03008041A (es) | Proceso para la fabricacion de articulos moldeados. | |
PL1831239T3 (pl) | Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu | |
TW200726763A (en) | Novel compound | |
ZA200904270B (en) | Novel bis(dialkylamide) compounds, process for the preparation thereof and uses thereof | |
EP1559736A4 (en) | PROCESS FOR PREPARING RESIN COMPOSITIONS | |
PL1966099T3 (pl) | Kompozycja, fryta, emalia oraz ceramiczne komponenty i proces w celu ich uzyskania | |
WO2005012271A3 (en) | Process for the synthesis of biaryl oxazolidinones | |
HK1119166A1 (en) | A process for the purification of 10-deacetylbaccatine iii from 10- deacetyl-2-debenzoyl-2-pentenoylbaccatine iii | |
PL1627881T3 (pl) | Sposób otrzymywania topiramatu | |
ZA200801821B (en) | Process for the preparation of glycosylated interferon beta | |
EP1915380A4 (en) | PROCESS FOR THE SYNTHESIS OF N, N'-DISUBSTITUTED OXABISPIDINES | |
AR054152A1 (es) | Procedimiento para la preparacion de interferon beta glicosilado | |
PL378315A1 (pl) | Sposób wytwarzania nowego di-μ-(trifluorooctano)bis[((trimetylosililo)etylenu) srebra(I)] |